Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15913651rdf:typepubmed:Citationlld:pubmed
pubmed-article:15913651lifeskim:mentionsumls-concept:C0006801lld:lifeskim
pubmed-article:15913651lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:15913651lifeskim:mentionsumls-concept:C0037628lld:lifeskim
pubmed-article:15913651lifeskim:mentionsumls-concept:C1148575lld:lifeskim
pubmed-article:15913651lifeskim:mentionsumls-concept:C1176299lld:lifeskim
pubmed-article:15913651pubmed:issue1lld:pubmed
pubmed-article:15913651pubmed:dateCreated2005-6-7lld:pubmed
pubmed-article:15913651pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15913651pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15913651pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15913651pubmed:abstractTextHeavy chain only antibodies of camelids bind their antigens with a single domain, the VHH, which acquired adaptations relative to classical VHs to function in the absence of a VL partner. Additional CDR loop conformations, outside the canonical loop structures of VHs, broaden the repertoire of the antigen-binding site. The combined effects of part of the CDR3 that folds over the "former" VL binding site and framework-2 mutations to more hydrophilic amino acids, enhance the solubility of VHH domains and prevent VL pairing. cAbAn33, a VHH domain specific for the carbohydrate moiety of the variant surface glycoprotein of trypanosomes, has a short CDR3 loop that does not cover the former VL binding site as well as a VH-specific Trp47 instead of the VHH-specific Gly47. Resurfacing its framework-2 region (mutations Tyr37Val, Glu44Gly and Arg45Leu) to mimic that of a human VH restores the VL binding capacity. In solution, the humanised VHH behaves as a soluble, monomeric entity, albeit with reduced thermodynamic stability and affinity for its antigen. Comparison of the crystal structures of cAbAn33 and its humanised derivative reveals steric hindrance exerted by VHH-specific residues Tyr37 and Arg45 that prevent the VL domain pairing, whereas Glu44 and Arg45 are key elements to avoid insolubility of the domain.lld:pubmed
pubmed-article:15913651pubmed:languageenglld:pubmed
pubmed-article:15913651pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15913651pubmed:citationSubsetIMlld:pubmed
pubmed-article:15913651pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15913651pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15913651pubmed:statusMEDLINElld:pubmed
pubmed-article:15913651pubmed:monthJullld:pubmed
pubmed-article:15913651pubmed:issn0022-2836lld:pubmed
pubmed-article:15913651pubmed:authorpubmed-author:LorisRemyRlld:pubmed
pubmed-article:15913651pubmed:authorpubmed-author:WynsLodeLlld:pubmed
pubmed-article:15913651pubmed:authorpubmed-author:ConrathKatjaKlld:pubmed
pubmed-article:15913651pubmed:authorpubmed-author:MuyldermansSe...lld:pubmed
pubmed-article:15913651pubmed:authorpubmed-author:DecanniereKla...lld:pubmed
pubmed-article:15913651pubmed:authorpubmed-author:StijlemansBen...lld:pubmed
pubmed-article:15913651pubmed:authorpubmed-author:SchymkowitzJo...lld:pubmed
pubmed-article:15913651pubmed:authorpubmed-author:VinckeCécileClld:pubmed
pubmed-article:15913651pubmed:issnTypePrintlld:pubmed
pubmed-article:15913651pubmed:day1lld:pubmed
pubmed-article:15913651pubmed:volume350lld:pubmed
pubmed-article:15913651pubmed:ownerNLMlld:pubmed
pubmed-article:15913651pubmed:authorsCompleteYlld:pubmed
pubmed-article:15913651pubmed:pagination112-25lld:pubmed
pubmed-article:15913651pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15913651pubmed:meshHeadingpubmed-meshheading:15913651...lld:pubmed
pubmed-article:15913651pubmed:meshHeadingpubmed-meshheading:15913651...lld:pubmed
pubmed-article:15913651pubmed:meshHeadingpubmed-meshheading:15913651...lld:pubmed
pubmed-article:15913651pubmed:meshHeadingpubmed-meshheading:15913651...lld:pubmed
pubmed-article:15913651pubmed:meshHeadingpubmed-meshheading:15913651...lld:pubmed
pubmed-article:15913651pubmed:meshHeadingpubmed-meshheading:15913651...lld:pubmed
pubmed-article:15913651pubmed:meshHeadingpubmed-meshheading:15913651...lld:pubmed
pubmed-article:15913651pubmed:meshHeadingpubmed-meshheading:15913651...lld:pubmed
pubmed-article:15913651pubmed:meshHeadingpubmed-meshheading:15913651...lld:pubmed
pubmed-article:15913651pubmed:meshHeadingpubmed-meshheading:15913651...lld:pubmed
pubmed-article:15913651pubmed:meshHeadingpubmed-meshheading:15913651...lld:pubmed
pubmed-article:15913651pubmed:meshHeadingpubmed-meshheading:15913651...lld:pubmed
pubmed-article:15913651pubmed:meshHeadingpubmed-meshheading:15913651...lld:pubmed
pubmed-article:15913651pubmed:meshHeadingpubmed-meshheading:15913651...lld:pubmed
pubmed-article:15913651pubmed:year2005lld:pubmed
pubmed-article:15913651pubmed:articleTitleAntigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH.lld:pubmed
pubmed-article:15913651pubmed:affiliationLaboratorium voor Cellulaire en Moleculaire Immunologie, Vrije Universiteit Brussel, Pleinlaan 2, B-1050 Brussel, Belgium. kconrath@vub.ac.belld:pubmed
pubmed-article:15913651pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15913651pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15913651lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15913651lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15913651lld:pubmed